JP2019536447A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536447A5
JP2019536447A5 JP2019522944A JP2019522944A JP2019536447A5 JP 2019536447 A5 JP2019536447 A5 JP 2019536447A5 JP 2019522944 A JP2019522944 A JP 2019522944A JP 2019522944 A JP2019522944 A JP 2019522944A JP 2019536447 A5 JP2019536447 A5 JP 2019536447A5
Authority
JP
Japan
Prior art keywords
population
gene
item
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536447A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058615 external-priority patent/WO2018081476A2/en
Publication of JP2019536447A publication Critical patent/JP2019536447A/ja
Publication of JP2019536447A5 publication Critical patent/JP2019536447A5/ja
Priority to JP2022185536A priority Critical patent/JP2023010842A/ja
Pending legal-status Critical Current

Links

JP2019522944A 2016-10-27 2017-10-26 Ｔ細胞療法のウイルス法 Pending JP2019536447A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022185536A JP2023010842A (ja) 2016-10-27 2022-11-21 Ｔ細胞療法のウイルス法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662413814P 2016-10-27 2016-10-27
US62/413,814 2016-10-27
US201762452081P 2017-01-30 2017-01-30
US62/452,081 2017-01-30
PCT/US2017/058615 WO2018081476A2 (en) 2016-10-27 2017-10-26 Viral methods of t cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022185536A Division JP2023010842A (ja) 2016-10-27 2022-11-21 Ｔ細胞療法のウイルス法

Publications (2)

Publication Number Publication Date
JP2019536447A JP2019536447A (ja) 2019-12-19
JP2019536447A5 true JP2019536447A5 (https=) 2021-01-14

Family

ID=62024054

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019522945A Pending JP2019531755A (ja) 2016-10-27 2017-10-26 遺伝子改変細胞を作製するウイルス法
JP2019522944A Pending JP2019536447A (ja) 2016-10-27 2017-10-26 Ｔ細胞療法のウイルス法
JP2022065676A Pending JP2022087214A (ja) 2016-10-27 2022-04-12 遺伝子改変細胞を作製するウイルス法
JP2022185536A Pending JP2023010842A (ja) 2016-10-27 2022-11-21 Ｔ細胞療法のウイルス法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019522945A Pending JP2019531755A (ja) 2016-10-27 2017-10-26 遺伝子改変細胞を作製するウイルス法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022065676A Pending JP2022087214A (ja) 2016-10-27 2022-04-12 遺伝子改変細胞を作製するウイルス法
JP2022185536A Pending JP2023010842A (ja) 2016-10-27 2022-11-21 Ｔ細胞療法のウイルス法

Country Status (8)

Country Link
US (2) US20190374576A1 (https=)
EP (2) EP3532075A4 (https=)
JP (4) JP2019531755A (https=)
CN (2) CN111344396A (https=)
AU (3) AU2017347854B2 (https=)
CA (2) CA3041831A1 (https=)
GB (3) GB2573664B (https=)
WO (2) WO2018081470A1 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
BR112017017812A2 (en) 2015-02-23 2018-04-10 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
EP3353296B1 (en) 2015-09-24 2020-11-04 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US12043843B2 (en) 2015-11-04 2024-07-23 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
WO2018075830A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
AU2017347854B2 (en) * 2016-10-27 2022-12-08 Intima Bioscience, Inc. Viral methods of T cell therapy
CA3042179A1 (en) 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
EP3645021A4 (en) * 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
BR112020008568A2 (pt) 2017-11-09 2020-10-06 Sangamo Therapeutics, Inc. modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
AU2018378479B2 (en) 2017-12-05 2025-03-13 Vertex Pharmaceuticals Incorporated CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
US11713446B2 (en) * 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
US11566236B2 (en) 2018-02-05 2023-01-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
US11268077B2 (en) 2018-02-05 2022-03-08 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CA3091491A1 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of human foxp3 in gene edited t cells
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
AU2019261438B2 (en) * 2018-04-27 2024-08-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of FOXP3 in edited CD34+ cells
KR20210005240A (ko) * 2018-05-03 2021-01-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포
US20210322473A1 (en) * 2018-07-18 2021-10-21 The General Hospital Corporation Modified t cells and methods of their use
US20210277120A1 (en) * 2018-07-18 2021-09-09 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
CN110818802B (zh) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 一种嵌合t细胞受体star及其应用
US20220056479A1 (en) * 2018-12-17 2022-02-24 Cure Genetics Co., Ltd. Method For Delivering Gene In Cells
EP3921419B1 (en) * 2019-02-08 2026-04-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Sirt2-ablated chimeric t cells
EP3927730A4 (en) 2019-02-20 2022-12-21 Rutgers, The State University of New Jersey EXPANSION OF NATURAL KILLER CELLS AND CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS
US20220154170A1 (en) * 2019-03-01 2022-05-19 Fred Hutchinson Cancer Research Center Protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
SG11202110613SA (en) * 2019-03-27 2021-10-28 Res Inst Nationwide Childrens Hospital Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses
US20220213469A1 (en) * 2019-04-30 2022-07-07 The Broad Institute, Inc. Methods and compositions for barcoding nucleic acid libraries and cell populations
AU2020288829A1 (en) * 2019-06-04 2021-12-02 Nkarta, Inc. Combinations of engineered natural killer cells and engineered T cells for immunotherapy
EP4017988A4 (en) * 2019-08-19 2023-09-27 The Board Of Trustees Of The Leland Stanford Junior University METHODS AND COMPOSITIONS FOR ENHANCEMENT AAV-MEDIATED HOMOLOGUE RECOMBINATION USING RIBONUCLEOTIDE REDUCTASE INHIBITORS
GB201913898D0 (en) * 2019-09-26 2019-11-13 Lightbio Ltd Nucleic acid construct
IL291935A (en) * 2019-10-08 2022-06-01 Pact Pharma Inc Methods for immunotherapy of genetically modified autologous t cells
IL293946A (en) * 2019-12-18 2022-08-01 Editas Medicine Inc Engineered cells for therapy
KR20220147614A (ko) * 2020-02-28 2022-11-03 제넨테크, 인크. 일차 골수 세포에서의 효율적인 유전체 편집
CN111420025B (zh) * 2020-04-28 2021-06-11 中国药科大学 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
AU2021392094A1 (en) * 2020-12-01 2023-07-06 Lepton Pharmaceuticals Ltd. Methods for enhancing therapeutic efficacy of isolated cells for cell therapy
WO2022125633A1 (en) * 2020-12-08 2022-06-16 The Regents Of The University Of California Crispr ribonucleoprotein complex genome editing of human innate immune cells
CN113046357B (zh) * 2021-01-25 2023-05-16 柳州市柳铁中心医院 一种乐伐替尼耐药基因dusp9、其筛选方法及应用
CN112941105A (zh) * 2021-02-08 2021-06-11 江西农业大学 一种m6A“阅读器”YTHDF2基因改造方法及其应用
CN114058619B (zh) * 2021-11-19 2023-11-14 中国农业科学院兰州兽医研究所 Riplet敲除细胞系的构建及作为小核糖核酸病毒科病毒疫苗生产细胞系的应用
CN114621929B (zh) * 2021-12-21 2023-05-30 河南省肿瘤医院 一种抗肿瘤树突状细胞及其制备方法、表达载体及应用
WO2023178292A1 (en) * 2022-03-16 2023-09-21 Regents Of The University Of Minnesota Genetically engineered t cell for cell therapy
AU2023353199A1 (en) * 2022-09-27 2025-03-20 Genentech, Inc. Inhibition of genotoxic stress to improve t cell engineering
EP4661970A1 (en) * 2023-02-07 2025-12-17 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Therapeutic base editing
WO2024220789A1 (en) * 2023-04-21 2024-10-24 Regents Of The University Of Minnesota Cell lines and methods for producing recombinant adeno-associated virus
WO2025179160A1 (en) * 2024-02-21 2025-08-28 Research Institute At Nationwide Children's Hospital Methods of increasing nk cell efficacy through inhibition of v-domain ig suppressor of t cell activation (vista)
CN121595402B (zh) * 2026-01-28 2026-04-17 信纳克(北京)生化标志物检测医学研究有限责任公司 用于鉴别异基因造血干细胞移植后腹泻致病成因的试剂盒与鉴别系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078540A1 (en) * 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1
AU2013329186B2 (en) * 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US9937207B2 (en) * 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
WO2014183066A2 (en) * 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
AU2014266833B2 (en) * 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
EP3441468B1 (en) * 2013-10-17 2021-05-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2015161276A2 (en) * 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20170335331A1 (en) * 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
CA2985650A1 (en) * 2015-05-13 2016-11-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Enhancing endonuclease based gene editing in primary cells
GB2592821B (en) * 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
JP2019509738A (ja) * 2016-03-11 2019-04-11 ブルーバード バイオ， インコーポレイテッド ゲノム編集された免疫エフェクター細胞
EP4628587A3 (en) * 2016-04-15 2026-02-25 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
WO2018073391A1 (en) * 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
AU2017347854B2 (en) * 2016-10-27 2022-12-08 Intima Bioscience, Inc. Viral methods of T cell therapy
EP3645021A4 (en) * 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
BR112020008568A2 (pt) * 2017-11-09 2020-10-06 Sangamo Therapeutics, Inc. modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)

Similar Documents

Publication Publication Date Title
JP2019536447A5 (https=)
JP2023010842A (ja) Ｔ細胞療法のウイルス法
JP2023055884A5 (https=)
EP3368689B1 (en) Composition for modulating immune responses by use of immune cell gene signature
US11186825B2 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1
US11180730B2 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3
JP2019531755A5 (https=)
JP2022519595A5 (https=)
JP2018522072A5 (https=)
US20240316100A1 (en) Engineered t cells
KR20240005804A (ko) 개선된 조작된 키메라 스캐폴드 및 다중화된 억제성 rna 클러스터
Huang et al. Combination of miRNA148a-3p binding sites and C5–12 promoter in rAAV vector synergistically reduces antigen presentation and transgene immunity
US20090060889A1 (en) Ii-RNAi involved Ii suppression in cancer immunotherapy
Wang et al. Rational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators
US20240366668A1 (en) Nkg2d car cells expressing il-18 for adoptive cell therapy
WO2020164167A1 (zh) 一种用于通用型car-t制备的重组腺相关病毒载体及其构建方法和应用
CN1807647A (zh) rep基因表达质粒，RBE顺式元件定点整合体系及其制备方法和应用
HK40097024A (zh) 用於工程改造和选择具有期望表型的car t细胞的组合物和方法
HK40032623A (en) Viral methods of making genetically modified cells
HK40018037A (en) Viral methods of t cell therapy
NZ547388A (en) Use of interfering RNA in the production of transgenic animals